A cash-burning single-product biotech where analysts project more than doubling from current levels, but persistent earnings misses, deeply negative free cash flow, and a heavily defensive options market reflect the substantial execution risk that stands between the current price and the upside scenario.
Thesis pillars
- Catastrophic Cash Burn No Moat→Stable
- Single Product Concentration Binary Risk→Stable
- Persistent Earnings Miss Track Record→Stable
- +2 more pillars — see the Why tab for full reasoning
Crinetics Pharmaceuticals, Inc. (CRNX) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $42.23: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality.
Crinetics Pharmaceuticals develops small-molecule therapies targeting peptide hormone GPCRs for endocrine diseases. PALSONIFY (paltusotine), the first once-daily oral acromegaly treatment, received FDA approval September 25, 2025, and became commercially available in the U.S. in... Read more
Sell if holding. Engine safety override at $42.23: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.7/10, moderate confidence.
Passes 7/8 gates (positive momentum, favorable risk/reward ratio, clean insider activity, news boost analyst cluster(3), earnings proximity no date, semi cycle peak clear, materials cycle peak clear). Suitability: speculative.
About Crinetics Pharmaceuticals, Inc.
About Crinetics Pharmaceuticals, Inc.
Crinetics Pharmaceuticals received FDA approval for PALSONIFY (paltusotine) on September 25, 2025, making it the first once-daily oral somatostatin receptor ligand for acromegaly, a rare pituitary disorder affecting approximately 11,500 actively managed patients in the U.S. Atumelnant is in Phase 3 development for congenital adrenal hyperplasia (CALM-CAH first patient randomized December 2025) and plans a Phase 2/3 study in ACTH-dependent Cushing's disease in the first half of 2026. CRN09682, a novel drug conjugate targeting SST2-expressing tumors, received its first patient dose in November 2025.
Crinetics generates commercial revenue from PALSONIFY through specialty pharmacy distribution, targeting the estimated 11,500 actively managed U.S. acromegaly patients using a specialized commercial organization focused on endocrinologists and pituitary surgeons. PALSONIFY holds FDA orphan drug designation for acromegaly, and in February 2026 the EMA's Committee for Human Medicinal Products adopted a positive opinion recommending EU marketing authorization, with a potential European Commission decision in the first half of 2026. Commercialization in Japan is licensed exclusively to SKK. Manufacturing relies on third-party contract manufacturers. Paltusotine is also in Phase 3 clinical development for carcinoid syndrome associated with neuroendocrine tumors (CAREFNDR study, first patient November 2025), which if approved would address an estimated 18,000-34,000 potential U.S. candidates.
Show full overview
Crinetics had an accumulated deficit of $1.4 billion at December 31, 2025, with the 10-K identifying paltusotine as the primary financial dependency of the business. The Phase 3 CALM-CAH and Phase 3 CAREFNDR trials represent binary readouts that, if unfavorable, could impair the company's path to profitability. Crinetics may need to seek additional financing through public or private equity or debt depending on clinical outcomes and operating plans, as disclosed in the liquidity discussion of the 10-K.
See also: Healthcare · Biotechnology
From Crinetics Pharmaceuticals, Inc.'s most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-07-06Recent Developments — Crinetics Pharmaceuticals, Inc.
Latest news
- NEWS This Honeywell Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday — benzinga Jul 2, 2026 neutral
- NEWS UBS Initiates Coverage On Crinetics Pharmaceuticals with Buy Rating, Announces Price Target of $55 — benzinga Jul 2, 2026 positive
- NEWS HC Wainwright & Co. Reiterates Buy on Crinetics Pharmaceuticals, Maintains $81 Price Target — benzinga Jun 15, 2026 positive
- NEWS Reported Sunday, Crinetics Presents Up To Two-Year PATHFNDR Open-Label Extension Data At ENDO 2026 Confirming PALSONIFY — benzinga Jun 15, 2026 positive
- NEWS Reported Sunday, Crinetics Presents Phase 2 Data For Atumelnant In CAH Showing 67% Mean Reduction In Androstenedione Lev — benzinga Jun 15, 2026 positive
Generated 2026-07-06T03:20:32Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHProductPALSONIFY (paltusotine)10-K Item 1A: 'We currently primarily depend on the success of paltusotine, approved as PALSONIFY in the U.S.'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02MEDIUMJeff Knight, Chief Development and Operating Officer, notified Crinetics of his resignation effective on or about April 10, 2026, to pursue another opportunity. No disagreement cited. All managerial responsibilities and direct reports to be reassigned to executive leadership team.SEC filing →
- 2026-04-10Item 5.02MEDIUMJeff Knight's resignation as Chief Development and Operating Officer became effective April 10, 2026. Company entered Independent Consultant Agreement with Knight for transitional services at $400/hour (up to 20 hours/month) through April 10, 2027.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Technicals below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $42.23: Quality below floor (1.6 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 5.7/10 and A.R:R 4.8:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 14%; Below-average business quality. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $39.27. Score 5.7/10, moderate confidence.
Take-profit target: $72.33 (+71.3% upside). Prior stop was $39.27. Stop-loss: $39.27.
Concentration risk — Product: PALSONIFY (paltusotine); Quality below floor (1.6 < 4.0).
Crinetics Pharmaceuticals, Inc. trades at a P/E of N/A (forward -10.2). TrendMatrix value score: 9.0/10. Verdict: Sell.
22 analysts cover CRNX with a consensus score of 4.2/5. Average price target: $83.
What does Crinetics Pharmaceuticals, Inc. do?Crinetics Pharmaceuticals develops small-molecule therapies targeting peptide hormone GPCRs for endocrine diseases....
Crinetics Pharmaceuticals develops small-molecule therapies targeting peptide hormone GPCRs for endocrine diseases. PALSONIFY (paltusotine), the first once-daily oral acromegaly treatment, received FDA approval September 25, 2025, and became commercially available in the U.S. in October 2025. Atumelnant for congenital adrenal hyperplasia and CRN09682 for SST2-expressing tumors are in active clinical development.